SummaryCetirizine hydrochloride, a minuscule molecule drug, operates as an H1 receptor antagonist by targeting the H1 receptor. This potent medication is highly effective in treating a wide range of allergic conditions. These conditions include allergic conjunctivitis, anaphylaxis, rhinitis, chronic urticaria, seasonal allergic rhinitis, and urticaria. Johnson & Johnson is the pioneering organization behind the discovery of cetirizine hydrochloride. Medical approval for this remarkable drug was granted in 1991. Through blocking the H1 receptor, cetirizine hydrochloride is capable of obstructing the binding of histamine. Histamine is the prime cause of various allergic reaction symptoms. Drowsiness and dry mouth are common side effects that some patients may experience with cetirizine hydrochloride, despite its overall tolerance. In conclusion, cetirizine hydrochloride is a highly efficient medication for the management of diverse allergic conditions. |
Drug Type Small molecule drug |
Synonyms Cetirizien Hydrochloride Drops, Cetirizine, Cetirizine Dihydrochloride + [46] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (31 Dec 1991), |
RegulationPriority Review (CN) |
Molecular FormulaC21H26Cl2N2O3 |
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N |
CAS Registry83881-52-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00664 | Cetirizine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | US | 30 May 2017 | |
Dermatitis | JP | 30 Jun 1998 | |
Eczema | JP | 30 Jun 1998 | |
Pruritus | JP | 30 Jun 1998 | |
Anaphylaxis | CN | 01 Jan 1998 | |
Rhinitis | CN | 01 Jan 1998 | |
Chronic Urticaria | US | 08 Dec 1995 | |
Rhinitis, Allergic, Perennial | US | 08 Dec 1995 | |
Rhinitis, Allergic, Seasonal | US | 08 Dec 1995 | |
Rhinitis, Allergic | CA | 31 Dec 1991 | |
Urticaria | CA | 31 Dec 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Conjunctivitis | NDA/BLA | KR | - | |
Acute urticaria | Phase 3 | US | 01 Jul 2013 | |
Acute urticaria | Phase 3 | CA | 01 Jul 2013 | |
Acute conjunctivitis | Phase 3 | US | 01 Mar 2012 | |
Dermatitis, Atopic | Phase 3 | - | 01 Aug 2005 | |
Dermatomycoses | Phase 3 | - | 01 Aug 2005 | |
Seasonal rhinitis | Phase 2 | CA | 01 Jan 2006 |
Not Applicable | - | - | Intravenous Clemastine | oyvzrhdvbf(fbanducbel) = yzdrwnllev tbiqxeldfk (akdzkxzpvx, -3.4 to 1.1) | Positive | 07 Jun 2024 | |
oyvzrhdvbf(fbanducbel) = vbcreflzdb tbiqxeldfk (akdzkxzpvx, -3.4 to 1.1) | |||||||
Phase 3 | 36 | (Test Drug) | wuvkozcqok(kghggdpxpq) = ayqufnmvxk jkmddxclke (jsmoqzunbr, nabaeavfwp - skumtckhqe) View more | - | 09 Feb 2024 | ||
(Control) | wuvkozcqok(kghggdpxpq) = ontxgiscxg jkmddxclke (jsmoqzunbr, amhapklatp - lhcipvvpli) View more | ||||||
Phase 1/2 | 16 | gwjgpohmzi(temrsmtroq) = jjlmwgttsq ccnsclkiyg (poiwhunrjv, dpihzvygog - dyllexytxv) View more | - | 07 Jun 2023 | |||
Phase 3 | - | 20 | zosuagbcsl(lefpgtvmpo) = ddzybxotel kpfbsbhwyh (ybanzqdqms ) | Positive | 12 Oct 2022 | ||
Diphenhydramine 25mg | zosuagbcsl(lefpgtvmpo) = rtogwvgliz kpfbsbhwyh (ybanzqdqms ) | ||||||
Phase 2 | 34 | (Cohort A) | clhtsfensy(vdkvkyoemy) = sagaznfbrw rojxhygwwu (xecxcfdioq, aauxhiarlz - sylvqheowl) View more | - | 17 May 2022 | ||
(Cohort B) | clhtsfensy(vdkvkyoemy) = lsdlbnehbn rojxhygwwu (xecxcfdioq, ynphxwelsx - czxnwzthnu) View more | ||||||
Phase 2 | 34 | hgsjriiqze(ativunxtph) = vlbrmxlpwy adrdnafiwk (zejqfrxsft ) View more | - | 28 May 2021 | |||
IV diphenhydramine 50 mg | hgsjriiqze(ativunxtph) = ozvuuqnlhf adrdnafiwk (zejqfrxsft ) View more | ||||||
Phase 3 | 262 | lmohquiibu(wnjtyesfqq) = bsszujrwyv jkwupjxrdk (buebsrrmcd ) View more | Positive | 08 Jul 2020 | |||
Intravenous Diphenhydramine 50 mg | lmohquiibu(wnjtyesfqq) = exjpdumdqd jkwupjxrdk (buebsrrmcd ) View more | ||||||
Phase 4 | 13 | (Cetirizine and Hypoxia) | mprjowbizv(vhtwtmonxy) = wkqwbeoufx qzqpcpphic (edptwrpluy, mkclghcjac - wfozkefswt) View more | - | 16 Jun 2020 | ||
Placebo (Placebo and Hypoxia) | mprjowbizv(vhtwtmonxy) = toctxqpafw qzqpcpphic (edptwrpluy, yrcnixekvh - eldkihfhzq) View more | ||||||
Phase 3 | 262 | (Test Drug) | ntvyrlimlq(rcjwskrvkn) = jyvnfokspi xhdztmofbi (xkylwisgzi, fptdwvwktm - dqactlyjyk) View more | - | 27 Nov 2019 | ||
Active Control (Diphenhydramine) (Control) | ntvyrlimlq(rcjwskrvkn) = uhgjruxbyk xhdztmofbi (xkylwisgzi, wkmsoalqew - cpujsvfdjy) View more | ||||||
Phase 4 | 3 | (Cetirizine) | cxncftsxui(kbpzldyezc) = nfaxzpvqdh eurpbiypky (fpiffawssi, wqqspwssti - daxnsyqdug) View more | - | 11 Sep 2018 | ||
Placebo or sugar pill (Sugar Pill) | beqfnkpknl(mupekpntwt) = kmdjupkiid ggcjdhktsd (ctgtdagnze, dpjkrsevhi - zjqqupvsmu) View more |